Cantor Fitzgerald reiterated their overweight rating on shares of Vincerx Pharma (NASDAQ:VINC - Free Report) in a report issued on Tuesday morning, Benzinga reports.
Vincerx Pharma Price Performance
VINC stock traded down $3.72 on Tuesday, reaching $1.06. The company's stock had a trading volume of 15,254,971 shares, compared to its average volume of 1,284,204. The firm has a fifty day moving average of $4.22 and a two-hundred day moving average of $2.10. The company has a market capitalization of $22.69 million, a P/E ratio of -0.56 and a beta of 1.09. Vincerx Pharma has a 52 week low of $0.61 and a 52 week high of $9.37.
Institutional Investors Weigh In On Vincerx Pharma
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Susquehanna International Group LLP acquired a new position in Vincerx Pharma during the 1st quarter valued at about $28,000. Goldman Sachs Group Inc. increased its stake in shares of Vincerx Pharma by 21.3% during the second quarter. Goldman Sachs Group Inc. now owns 36,126 shares of the company's stock valued at $48,000 after acquiring an additional 6,334 shares during the period. Rhumbline Advisers bought a new stake in Vincerx Pharma during the first quarter worth approximately $53,000. ExodusPoint Capital Management LP acquired a new stake in Vincerx Pharma in the second quarter worth approximately $132,000. Finally, Walleye Capital LLC bought a new position in Vincerx Pharma during the 2nd quarter valued at $176,000. 44.02% of the stock is currently owned by institutional investors.
Vincerx Pharma Company Profile
(
Get Free Report)
Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.
Recommended Stories
Before you consider Vincerx Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vincerx Pharma wasn't on the list.
While Vincerx Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
